Small cell lung cancer, version 2.2022: NCCN Clinical Practice Guidelines in Oncology Guidelines


Authors: Ganti, A. K. P.; Loo, B. W. Jr; Bassetti, M.; Blakely, C.; Chiang, A.; D'Amico, T. A.; D'Avella, C.; Dowlati, A.; Downey, R. J.; Edelman, M.; Florsheim, C.; Gold, K. A.; Goldman, J. W.; Grecula, J. C.; Hann, C.; Iams, W.; Iyengar, P.; Kelly, K.; Khalil, M.; Koczywas, M.; Merritt, R. E.; Mohindra, N.; Molina, J.; Moran, C.; Pokharel, S.; Puri, S.; Qin, A.; Rusthoven, C.; Sands, J.; Santana-Davila, R.; Shafique, M.; Waqar, S. N.; Gregory, K. M.; Hughes, M.
Title: Small cell lung cancer, version 2.2022: NCCN Clinical Practice Guidelines in Oncology
Abstract: The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. This selection for the journal focuses on metastatic (known as extensive-stage) SCLC, which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms and prolong survival in most patients with extensive-stage disease. Smoking cessation counseling and intervention should be strongly promoted in patients with SCLC and other high-grade neuroendocrine carcinomas. The “Summary of the Guidelines Updates” section in the SCLC algorithm outlines the most recent revisions for the 2022 update, which are described in greater detail in this revised Discussion text. © National Comprehensive Cancer Network, Inc. 2021.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 19
Issue: 12
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2021-12-01
Start Page: 1441
End Page: 1464
Language: English
DOI: 10.6004/jnccn.2021.0058
PUBMED: 34902832
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 1 February 2022 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Robert J Downey
    254 Downey